These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 702336)

  • 1. N,N-Di-n-propyl dopamine: a qualitatively different dopamine vascular agonist.
    Kohli JD; Goldberg LI; Volkman PH; Cannon JG
    J Pharmacol Exp Ther; 1978 Oct; 207(1):16-22. PubMed ID: 702336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consistent unmasking of dopamine-induced dilation of the canine femoral vascular bed.
    Listinsky JJ; Kohli JD; Goldberg LI
    J Pharmacol Exp Ther; 1980 Dec; 215(3):662-7. PubMed ID: 6108364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood pressure lowering effects of N,N-di-n-propyl-dopamine in rats: evidence for stimulation of peripheral dopamine receptors leading to inhibition of sympathetic vascular tone.
    Cavero I; Lefèvre-Borg F; Gomeni R
    J Pharmacol Exp Ther; 1981 Aug; 218(2):515-24. PubMed ID: 7252851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ring fluorination on the cardiovascular actions of dopamine and norepinephrine in the dog.
    Goldberg LI; Kohli JD; Cantacuzene D; Kirk KL; Creveling CR
    J Pharmacol Exp Ther; 1980 Jun; 213(3):509-13. PubMed ID: 6894165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the cardiovascular actions of dopamine and epinine in the dog.
    Itoh H; Kohli JD; Rajfer SI; Goldberg LI
    J Pharmacol Exp Ther; 1985 Apr; 233(1):87-93. PubMed ID: 2858584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects of the novel inotropic agent, ibopamine, with epinine, dopamine and fenoldopam on renal vascular dopamine receptors in the anesthetized dog.
    Nichols AJ; Smith JM; Shebuski RJ; Ruffolo RR
    J Pharmacol Exp Ther; 1987 Aug; 242(2):573-8. PubMed ID: 2886644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primate cardiovascular responses mediated by dopamine receptors: effects of N,N-di-n-propyldopamine and LY171555.
    Hahn RA; MacDonald BR
    J Pharmacol Exp Ther; 1984 Apr; 229(1):132-8. PubMed ID: 6707929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypotensive effects of N,N-din-n-propylodopamine in the anesthetized dog: comparison with sodium nitroprusside.
    Fennell WH; Kohli JD; Goldberg LI
    J Cardiovasc Pharmacol; 1980; 2(3):247-55. PubMed ID: 6156323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure activity relationships of N-substituted dopamine derivatives as agonists of the dopamine vascular and other cardiovascular receptors.
    Kohli JD; Weder AB; Goldberg LI; Ginos JZ
    J Pharmacol Exp Ther; 1980 May; 213(2):370-4. PubMed ID: 7365696
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of dopamine, N-N-di-n-propyl dopamine, and (R)- and (S)-sulpiride on guinea pig blood pressure.
    Horn PT; Kohli JD; Goldberg LI
    J Cardiovasc Pharmacol; 1982; 4(4):668-75. PubMed ID: 6181343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of presynaptic receptors in the cardiovascular actions of N,N-di-n-propyldopamine in the cat and dog.
    Massingham R; Dubocovich ML; Langer SZ
    Naunyn Schmiedebergs Arch Pharmacol; 1980 Oct; 314(1):17-28. PubMed ID: 7442823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereoselectivity of S- and R-sulpiride for pre- and postsynaptic dopamine receptors in the canine kidney.
    Bass AS; Robie NW
    J Pharmacol Exp Ther; 1984 Apr; 229(1):67-71. PubMed ID: 6707948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist.
    Hahn RA; Wardell JR; Sarau HM; Ridley PT
    J Pharmacol Exp Ther; 1982 Nov; 223(2):305-13. PubMed ID: 6127401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dopamine receptor agonists and antagonists at peripheral neuronal and vascular dopamine receptors in the anaesthetised dog.
    Hilditch A; Drew GM
    J Cardiovasc Pharmacol; 1984; 6(3):460-9. PubMed ID: 6202973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the cardiovascular actions of N,N-di-n-propyl dopamine and sodium nitroprusside in conscious and chloralose-anaesthetised dogs.
    O'Connor SE; Smith GW; Brown RA
    J Cardiovasc Pharmacol; 1982; 4(3):493-9. PubMed ID: 6177948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cardiovascular actions of dopamine and the effects of central and peripheral catecholaminergic receptor blocking drugs.
    Setler PE; Pendleton RG; Finlay E
    J Pharmacol Exp Ther; 1975 Mar; 192(3):702-12. PubMed ID: 1120964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms mediating the positive inotropic and chronotropic changes induced by dopexamine in the anesthetized dog.
    Bass AS; Kohli JD; Lubbers N; Goldberg LI
    J Pharmacol Exp Ther; 1987 Sep; 242(3):940-4. PubMed ID: 2888876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological studies with the alpha 2-adrenoceptor antagonist midaglizole. Part I: Respiratory and cardiovascular systems.
    Hirohashi M; Takasuna K; Yamashita N; Tamura K
    Arzneimittelforschung; 1991 Jan; 41(1):9-18. PubMed ID: 1675573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of dopamine (DA) and SKF 82526, a selective DA1-receptor agonist, on vascular resistances in the canine forelimb.
    Grega GJ; Barrett RJ; Adamski SW; Lokhandwala MF
    J Pharmacol Exp Ther; 1984 Jun; 229(3):756-62. PubMed ID: 6144791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combined effects of dopamine (DA) and the DA antagonists EGYT-2509, chlorpromazine and haloperidol on the kidney function.
    Kövér G; Fekete M; Tost H; Szemerédi K
    Acta Physiol Hung; 1988; 72(3-4):321-33. PubMed ID: 3250211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.